Daily Respiratory Research Analysis
Three impactful respiratory studies stood out today. A Nature paper defines macaque pathogenesis of bovine-origin H5N1 clade 2.3.4.4b, informing pandemic risk and countermeasures. An emulated targeted trial in ventilated COVID-19 patients shows empirical antibiotics at intubation were associated with fewer superinfections and lower mortality, while a Respirology study identifies CD131 antagonism as a promising disease-modifying strategy for asthma–COPD overlap that also prevents viral exacerbati
Summary
Three impactful respiratory studies stood out today. A Nature paper defines macaque pathogenesis of bovine-origin H5N1 clade 2.3.4.4b, informing pandemic risk and countermeasures. An emulated targeted trial in ventilated COVID-19 patients shows empirical antibiotics at intubation were associated with fewer superinfections and lower mortality, while a Respirology study identifies CD131 antagonism as a promising disease-modifying strategy for asthma–COPD overlap that also prevents viral exacerbations.
Research Themes
- Zoonotic respiratory viruses and pandemic preparedness
- Antibiotic strategies in ventilated respiratory failure
- Novel immunologic targets for airway disease modification
Selected Articles
1. Pathogenesis of bovine H5N1 clade 2.3.4.4b infection in macaques.
This preclinical study establishes disease features of bovine-origin H5N1 clade 2.3.4.4b infection in macaques, a translational model for humans. The work delineates respiratory tract infection and pathology, creating a platform to test vaccines/antivirals and to assess spillover risk.
Impact: Defines a robust NHP pathogenesis model for a rapidly evolving zoonotic influenza threat, enabling high-confidence countermeasure evaluation.
Clinical Implications: Direct clinical practice impact is indirect; however, a validated macaque model accelerates development and testing of vaccines/antivirals and informs risk assessments for human exposure.
Key Findings
- Established a macaque model of disease for bovine-origin H5N1 clade 2.3.4.4b.
- Defined respiratory tract infection and pathological features consistent with severe influenza.
- Provides a translational platform to evaluate vaccines and antivirals against this clade.
- Supports zoonotic spillover risk assessment for mammalian-adapted H5N1.
Methodological Strengths
- Use of a non-human primate model enhances translational relevance.
- Systematic pathogenesis characterization across respiratory tissues.
Limitations
- Abstract does not detail sample size or comprehensive virological metrics.
- Preclinical animal findings require validation in diverse strains and settings.
Future Directions: Quantify transmission parameters, immune correlates of protection, and evaluate candidate vaccines/antivirals across H5N1 genotypes using this NHP model.
Since early 2022, highly pathogenic avian influenza (HPAI) H5N1 virus infections have been reported in wild aquatic birds and poultry throughout the USA with spillover into several mammalian species
2. Empirical antibiotic therapy improves outcomes in mechanically ventilated patients with COVID-19: An emulated targeted trial within a prospective, multicentre cohort study.
In a propensity score–matched emulated targeted trial of 2,580 ventilated COVID-19 patients, empirical antibiotics given within 24 hours of intubation were associated with fewer pulmonary superinfections, shorter ventilation and ICU stays, and reduced 28-day mortality. Findings support targeted early antibiotic use in high-risk ventilated COVID-19 under stewardship.
Impact: Addresses a common, high-stakes decision at intubation using modern causal inference on a large multicentre cohort, with clinically meaningful outcomes.
Clinical Implications: Consider empirical antibiotics at intubation for ventilated COVID-19 patients at high risk of bacterial superinfection, integrated with local ecology and antimicrobial stewardship. Generalizability to non-pandemic viral pneumonias should be evaluated.
Key Findings
- After matching, empirical antibiotics at intubation reduced pulmonary superinfection (39% vs 47%, p<0.01).
- Shorter duration of mechanical ventilation (IRR 0.85, 95% CI 0.78–0.94) and ICU stay (IRR 0.89, 95% CI 0.82–0.97).
- Lower 28-day mortality (28% vs 32%; OR 0.76, 95% CI 0.61–0.94).
- Findings derived from a prospective multicentre cohort across 62 ICUs with emulated target trial design.
Methodological Strengths
- Emulated target trial with propensity score matching reduces confounding.
- Large, prospective, multicentre dataset spanning 62 ICUs increases external validity.
Limitations
- Observational design; residual confounding cannot be fully excluded.
- Applicability to non-COVID viral pneumonias and post-pandemic practice remains uncertain.
Future Directions: Randomized trials to confirm causal effects, optimize antibiotic selection/duration, and integrate biomarker-guided initiation in ventilated viral pneumonia.
BACKGROUND: Bacterial pulmonary superinfections develop in a substantial proportion of mechanically ventilated COVID-19 patients and are associated with prolonged mechanical ventilation requirements and increased mortality. Albeit recommended, evidence supporting the use of empirical antibiotics at intubation is weak and of low quality. The aim of this study was to elucidate the effect of empirical antibiotics, administered within 24 h of endotracheal intubation, on superinfections, duration of mechanical ventilation, and mortality in mechanically ventilated patients with COVID-19. METHODS: Emulated targeted trial by means of a propensity score-matched analysis of a prospective multicentre cohort study of consecutive mechanically ventilated patients admitted to 62 Spanish intensive care units suffering from COVID-19 between March 2020 and February 2021. RESULTS: Overall, 8532 critically ill COVID-19 patients were included, of which 2580 mechanically ventilated patients remained after matching. Empirical antibiotics were prescribed to 1665 (64%) at intubation. Pulmonary superinfections developed in 39% and 47% of patients treated with and without empirical antibiotics, respectively (p<0.01). Patients treated with empirical antibiotics had a shorter duration of mechanical ventilation (incidence risk ratio: 0.85 [95% confidence interval (CI), 0.78 - 0.94], p<0.01) and a reduced stay in the intensive care unit (incidence risk ratio: 0.89 [95% CI, 0.82 - 0.97] days, p<0.01). Mortality 28 days after endotracheal intubation was 28% in patients treated with empirical antibiotics as opposed to 32% in patients treated without (odds ratio: 0.76 [95% CI, 0.61 - 0.94], p<0.01). CONCLUSION: The administration of empirical antibiotics at intubation in mechanically ventilated COVID-19 patients was associated with a reduced incidence of pulmonary superinfections, a shorter duration of mechanical ventilation and intensive care unit stay, and a lower mortality rate. Notwithstanding these benefits, the applicability of these findings to other viral pneumonias and beyond the pandemic context remains uncertain. REGISTRATION: www. CLINICALTRIALS: gov (NCT04457505).
3. CD131 antagonism blocks inflammation, emphysema and fibrosis in an asthma-COPD overlap mouse model originating in early life.
In an ACO mouse model combining HDM sensitization and elastase injury, blocking CD131—a shared IL-3/IL-5/GM-CSF receptor subunit—attenuated mixed granulocytic inflammation, prevented airway hyperreactivity, fibrosis, and emphysema, and reduced RV1b-induced exacerbations without impairing viral clearance. CD131 integrates pathogenic axes in ACO, offering a disease-modifying target.
Impact: Proposes a single upstream target (CD131) to modulate multiple pathogenic pathways in ACO and shows protection against viral exacerbations, addressing a major unmet need.
Clinical Implications: Although preclinical, CD131 antagonism could evolve into a disease-modifying therapy for ACO by reducing inflammation and structural lung damage while preserving antiviral responses.
Key Findings
- Two-hit ACO model (HDM + elastase) reproduced AHR, mixed granulocytic inflammation, fibrosis, and emphysema.
- CD131 blockade reduced lung inflammation and prevented AHR, airway fibrosis, and emphysema.
- Type 2 inflammation/macrophage activation pathways were enriched in ACO and attenuated by CD131 antagonism.
- CD131 antagonism prevented RV1b-induced exacerbation without compromising viral clearance.
Methodological Strengths
- Mechanistically informed two-hit model capturing both asthma and COPD features.
- Use of both allergen/emphysema model and viral exacerbation model enhances relevance.
Limitations
- Preclinical mouse data; human translatability and safety of CD131 antagonism are unknown.
- Dose–response, durability, and off-target effects require further study.
Future Directions: Define pharmacology, safety, and biomarkers for CD131 antagonism; test in ACO patient-derived systems and early-phase clinical studies.
BACKGROUND AND OBJECTIVE: Asthma-COPD overlap (ACO) is characterized by patients exhibiting features of both asthma and COPD. Currently, there is no specific treatment for ACO. This study aimed to investigate the therapeutic potential of targeting CD131, a shared receptor subunit for IL-3, IL-5 and GM-CSF, in ACO development and in preventing acute viral exacerbations. METHODS: A two-hit mouse model of ACO was established by house dust mite (HDM) allergen sensitization to model asthma, and elastase treatment to model emphysema. In a separate model, human rhinovirus 1b (RV1b) was used to induce an acute asthma exacerbation. A neutralizing antibody against CD131 was used to block CD131 in vivo signalling. RESULTS: Mice exposed to HDM and elastase developed cardinal features for asthma and COPD, including airway hyperreactivity (AHR) and emphysema. A mixed granulocytic inflammatory profile was identified in the lungs, including expansion of monocyte-derived macrophages, neutrophils and eosinophils. RT-qPCR analysis detected heightened gene expression of Mmp12, Il5 and Il13. Transcriptomic analysis further revealed pathway enrichment for type 2 inflammation and macrophage activation. Blockade of CD131 effectively reduced the lung inflammation and prevented the development of AHR, airway fibrosis and emphysema. Interestingly, pathway enrichment for Th1 response and interferon production detected in the model was not affected by the treatment. Consistently, CD131 antagonism prevented RV1b-induced asthma exacerbation without compromising RV1b clearance. CONCLUSION: CD131 signalling coordinates multiple pathological pathways that drive airway inflammation and lung remodelling in ACO. Hence, CD131 antagonism represents a novel approach to combating the immunopathology in the complex ACO setting.